Related Experiment Videos
Epilepsy, atherosclerosis, myocardial infarction, and carbamazepine
Jean-Pierre de Chadarévian1, Agustin Legido, Daniel K Miles
1Department of Pathology and Laboratory Medicine, Drexel University College of Medicine, St. Christopher's Hospital for Children, Philadelphia, Pennsylvania 19134, USA. JD37@drexel.edu
Insights
Carbamazepine, an epilepsy medication, may increase the risk of atherosclerosis and heart attack in children. An 11-year-old boy on this drug for 10 years died with severe coronary atherosclerosis and myocardial infarction.
Area of Science:
- Pediatric Cardiology
- Neurology
- Pharmacology
Background:
- Certain antiepileptic drugs like phenytoin and phenobarbital are associated with a low incidence of myocardial infarction.
- Concerns exist regarding carbamazepine's potential to alter lipid profiles in children, possibly leading to atherosclerosis.
Observation:
- This report details the case of an 11-year-old boy with a history of epilepsy treated with carbamazepine for over a decade.
- The patient experienced a major seizure, rhabdomyolysis, and subsequent renal failure, leading to his death.
Findings:
- Autopsy revealed significant coronary atherosclerosis and myocardial infarction in the deceased child.
- These findings corroborate the potential link between long-term carbamazepine use and cardiovascular complications in pediatric patients.
Implications:
- The study highlights the need for careful monitoring of lipid profiles and cardiovascular health in children treated with carbamazepine.
- Further research is warranted to elucidate the mechanisms and long-term cardiovascular risks associated with carbamazepine in pediatric populations.
Abstract:
Epileptic patients receiving medications such as phenytoin or phenobarbital have been noted to have an exceedingly low incidence of myocardial infarction, but children treated with carbamazepine have shown alteration of their serum lipid profile that could predispose them to atherosclerosis. This report seems to corroborate this point and describes the findings in an 11-year-old boy who died following a major seizure, rhabdomyolysis, and renal failure. The autopsy demonstrated that he had marked coronary atherosclerosis and myocardial infarction. The child had been treated with carbamazepine for more than 10 years.